A Phase 1, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability and Pharmacokinetic Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 04 Jun 2019
Price : $35 *
At a glance
- Drugs TAS 119 (Primary) ; Paclitaxel
- Indications Colon cancer; Ovarian cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Taiho Pharmaceutical
- 04 Jun 2019 Results (n=26, dose escalation part) presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 12 Jun 2017 Planned End Date changed from 1 May 2017 to 1 Nov 2018.
- 12 Jun 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Nov 2018.